Table 2.

Standardized incidence ratios (SIRs) of AIDS- and non-AIDS-defining cancers by study site

	INI		VCCC
	N	SIR [95% CI]	N	SIR [95% CI]
AIDS-defining cancers	57	24.6 [18.7-31.9]	47	17.0 [12.5-22.6]
Kaposi Sarcoma	37	269 [189–371]	19	1157 [697–1807]
Non-Hodgkin Lymphoma	20	21.2 [12.9-32.7]	27	11.4 [7.5-16.6]
Cervix	0	0 [0–3.2]	1	2.7 [0.7-14.9]
Non-AIDS-defining cancers	45	1.4 [1.1-1.9]	81	1.3 [1.0-1.7]
Oral Cavity & Pharynx	3	1.7 [0.4-5.0]	2	1.2 [0.1-4.3]
Esophagus	1	1.0 [0–5.4]	1	2.1 [0.1-11.9]
Stomach	2	1.5 [0.2-5.5]	0	0 [0–5.2]
Small Intestine	0	0 [0–47.9]	1	4.2 [0.1-23.6]
Colon & Rectum	2	1.1 [0.1-4.1]	5	1.2 [0.4-2.9]
Anus	7	62.3 [25.1-128]	9	25.0 [11.4-47.5]
Liver	0	0 [0–8.6]	3	3.7 [0.8-10.7]
Biliary Tract	0	0 [0–19.4]	2	17.6 [2.1-63.5]
Pancreas	1	2.9 [0.1-16.1]	0	0 [0–4.8]
Larynx	3	4.6 [0.9-13.3]	2	4.4 [0.5-15.7]
Lung & Bronchus	4	3.0 [0.8-7.7]	11	2.8 [1.4-5.1]
Mediastinum	1	23.0 [0.6-128]	0	0 [0–161]
Soft Tissue Sarcoma	0	0 [0–1.06]	1	2.4 [0.1-13.4]
Squamous and basal cell skin cancers	9	1.9 [0.9-3.7]	28	Not available
Melanoma	0	0 [0–8.1]	2	0.6 [0.1-2.1]
Breast	5	1.3 [0.4-2.9]	1	0.2 [0–1.3]
Corpus Uterus	1	5.5 [0.1-30.8]	0	0 [0–7.7]
Ovary	1	3.0 [0.1-16.5]	1	3.1 [0.1-17.2]
Prostate	1	0.3 [0–1.6]	4	0.4 [0.1-1.0]
Testis	0	0 [0–16.1]	0	0 [0–4.7]
Urinary Bladder	0	0 [0–8.3]	3	2.6 [0.5-7.5]
Kidney	2	4.5 [0.5-16.2]	0	0 [0–2.2]
Brain & other CNS	0	0 [0–4.3]	0	0 [0–4.8]
Thyroid	0	0 [0–8.8]	0	0 [0–2.5]
Other Endocrine	0	0 [0–115]	1	10.0 [0.3-55.5]
Hodgkin Lymphoma	0	0 [0–12.2]	1	1.9 [0.1-10.5]
Myeloma	0	0 [0–12.3]	1	1.6 [0–9.0]
Leukemia	1	1.9 [0.1-10.7]	1	1.0 [0–5.6]
Mesothelioma	0	0 [0–181]	0	0 [0–84.9]
Other	1	1.0 [0–5.3]	1	1.7 [0–9.6]

Comparator population for INI SIRs: Belo Horizonte, MG, general population.

Comparator population for VCCC SIRs: Atlanta, GA, general population.

Abbreviations:

INI: Instituto Nacional de Infectologia Evandro Chagas, Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.

VCCC: Vanderbilt Comprehensive Care Clinic, Nashville, TN, USA.

CI: Confidence interval.